The brokerage firm downgraded the shares to "hold"
It's a rip-roaring start to the second quarter, with the stock market rallying on upbeat global manufacturing data. Among individual stocks making notable moves are online family care marketplace Care.com Inc (NYSE:CRCM), marketing analytics firm Comscore, Inc. (NASDAQ:SCOR), and pulmonary disease specialist Pulmatrix Inc (NASDAQ:PULM). Here's a quick look at what's moving the shares of CRCM, SCOR, and PULM.
CRCM Stock Eyes Lowest Close of 2019
Care.com stock is down 6.1% to trade at $18.56, on track to snap its five-day win streak, after a Wall Street Journal (WSJ) report suggested CRCM removed tens of thousands of unverified daycare listings ahead of a March 8 release of a WSJ article on the company. The stock dropped 12.5% on March 11, the first trading day after the original report was released, and is now down 28% from their March 4 five-year high of $25.81, headed toward its lowest close of the year.
There's room for analysts to adjust their outlooks on the sinking stock. While three of six brokerages maintain a "buy" or better rating, the average 12-month price target of $26.25 is a nearly 42% premium to current trading levels.
Comscore Sinks to Bottom of Nasdaq
The shares of Comscore are at the bottom of the Nasdaq, down 25.6% at $15.06, after the company's CEO abruptly resigned, citing "irreconcilable differences" with the board. Comscore's President Sarah Hofstetter also said she was stepping down.
A downgrade to "hold" from "buy" at SunTrust Robinson is only ramping up the selling pressure. The brokerage firm also slashed its SCOR price target by $6 to $21, explaining "the story has changed with the resignations."
More analysts could chime in, considering five of seven still carry "buy" or better ratings on the stock that's down more than 37% from its early March peak above $28. Plus, the consensus 12-month price target of $25.80 is a 73.1% premium to SCOR's current price.
New Partnership Fuels Pulmatrix Stock Surge
Pulmatrix shares have more than doubled today -- putting them at the top of the Nasdaq -- after the company teamed up with India's Cipla to develop PULM's Pulmazole, an inhaled version of its antifungal drug, itraconazole.This positive price action is welcome from an equity that was trading near record lows below $1 in early February. What's more, today's surge is being contained by PULM stock's 120-day moving average, which kept a tight lid on the shares in late 2018.